September 06, 2022

New Study Shows Paxlovid Decreases COVID Deaths for Older People

A new study indicates that Pfizer’s COVID-19 treatment, Paxlovid, significantly reduces deaths and hospitalizations for patients aged 65 years and older. According to recent data, adults who are 65 years or older account for 80 percent of COVID-19 deaths and more than half of COVID-19 hospitalizations in the United States thus far.

The Food and Drug Administration has also authorized Pfizer and Moderna booster shots that are specifically tailored to combat Omicron variants of COVID-19, which are currently the dominant strains circulating in the United States.

“Seniors have a heightened risk of death or complications if they contract COVID-19,” said Alliance Secretary-Treasurer Joseph Peters, Jr. “The results of this study are encouraging and confirm that vaccination and treatments like Paxlovid can do a lot to protect older Americans against severe illness.”